We are live on ! Find out more
SRRA

Sierra Oncology, Inc. Common Stock
SRRA

Delisted

SRRA was delisted on the 30th of June, 2022.

Back to rankings

109 hedge funds and large institutions have $1.06B invested in Sierra Oncology, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more first-time investments, than exits

New positions opened: 71 | Existing positions closed: 36

65% more capital invested

Capital invested by funds: $641M → $1.06B (+$417M)

45% more funds holding

Funds holding: 75 → 109 (+34)

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

13% less funds holding in top 10

Funds holding in top 10: 8 → 7 (-1)

38% less call options, than puts

Call options by funds: $8.79M | Put options by funds: $14.1M

Holders
109
Holders Change
+34
Holders Change %
+45.33%
% of All Funds
1.84%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.12%
New
71
Increased
17
Reduced
16
Closed
36
Calls
$8.79M
Puts
$14.1M
Net Calls
-$5.27M
Net Calls Change
-$8.73M

Top Buyers

Rank Fund Capital Flow
1
VI
Versor Investments
New York
+$82.9M
2
MF
Magnetar Financial
Illinois
+$58.1M
3
TAL
TIG Advisors LLC
New York
+$46.8M
4
BlackRock
BlackRock
New York
+$37.9M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$26.5M

Top Sellers

Rank Fund Capital Flow
1
FLSM
Frazier Life Sciences Management
California
-$77.2M
2
PHS
PFM Health Sciences
California
-$34.1M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$32M
4
Citadel Advisors
Citadel Advisors
Florida
-$24.2M
5
SI
Sofinnova Investments
California
-$18.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
51
Charles Schwab
California
$1.81M +$1.72M +32,828 New
Verition Fund Management
52
Verition Fund Management
Connecticut
$1.8M +$1.71M +32,662 New
SC
53
Sagefield Capital
Texas
$1.68M +$1.6M +30,500 New
CS
54
Credit Suisse
Switzerland
$1.47M +$1.4M +26,755 New
FM
55
Frazier Management
Washington
$1.12M -$1.8M -34,338 -63%
CSS
56
Cubist Systematic Strategies
Connecticut
$1.11M -$1.31M -25,007 -55%
WIC
57
Water Island Capital
New York
$1.08M +$1.03M +19,613 New
RhumbLine Advisers
58
RhumbLine Advisers
Massachusetts
$1.05M +$1M +19,058 New
WMSA
59
Weiss Multi-Strategy Advisers
New York
$1.02M +$979K +18,648 New
BCM
60
BCK Capital Management
Connecticut
$1.02M +$971K +18,500 New
GC
61
Guggenheim Capital
Illinois
$1.01M +$963K +18,354 New
PC
62
Paulson & Co
New York
$972K +$927K +17,675 New
GH
63
GAM Holding
Switzerland
$940K +$897K +17,100 New
NYLIM
64
New York Life Investment Management
New York
$918K +$876K +16,702 New
California State Teachers Retirement System (CalSTRS)
65
California State Teachers Retirement System (CalSTRS)
California
$906K +$864K +16,467 New
HA
66
Havens Advisors
New York
$789K +$753K +14,350 New
TMAM
67
Tokio Marine Asset Management
Japan
$786K +$750K +14,286 New
Skandinaviska Enskilda Banken (SEB)
68
Skandinaviska Enskilda Banken (SEB)
Sweden
$753K +$718K +13,685 New
EA
69
Ellsworth Advisors
Ohio
$738K -$14.8K -282 -2%
Squarepoint
70
Squarepoint
New York
$586K +$50.2K +957 +10%
UBS AM
71
UBS AM
Illinois
$573K +$546K +10,414 New
New York State Common Retirement Fund
72
New York State Common Retirement Fund
New York
$566K +$540K +10,300 New
Allianz Asset Management
73
Allianz Asset Management
Germany
$561K +$535K +10,200 New
TI
74
Telemetry Investments
New York
$552K +$527K +10,046 New
Barclays
75
Barclays
United Kingdom
$512K -$692K -13,196 -59%
1 2
3
4 5

SRRA Hedge Fund Activity: Q2 2022 in Review

109 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q2 2022, worth a combined $1.06B — up 65% from $641M a quarter earlier.

Buyers outnumbered sellers: 71 funds opened new SRRA positions and 36 closed out — a net gain of 35 holders — while 17 added to existing stakes and 16 trimmed.

The largest buyer was Versor Investments, opening a new position worth an estimated $82.9M. The largest seller was Frazier Life Sciences Management, cutting an estimated $77.2M.

  • 109 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q2 2022, up from 75 in Q1 2022.
  • Funds reported $1.06B of Sierra Oncology, Inc. Common Stock stock for Q2 2022, up 65% quarter-over-quarter.
  • 71 funds opened new Sierra Oncology, Inc. Common Stock positions in Q2 2022 and 36 closed out, a net change of +35 holders.
  • The largest Sierra Oncology, Inc. Common Stock buyer in Q2 2022 was Versor Investments, an estimated $82.9M added.
  • The largest Sierra Oncology, Inc. Common Stock seller in Q2 2022 was Frazier Life Sciences Management, an estimated $77.2M sold.

Based on aggregated 13F filings for Q2 2022.